Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Trillium Offer

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Jul 28, 2022 7:01am

227 Views

Post# 34856127

RE:RE:Trillium Offer

Better to give results and good one Or a deal before any buyout offer. ONC need a market cap well over the actual to see a buyout in multiple billions $. Tril was already over a billion when the buyout came out. Long way to go but it could go fast. Mr Parsons has 45k options to convert and I think he will want to convert them fast!

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario